OncoMatch/Clinical Trials/NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Is NCT06136559 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Nemtabrutinib and Ibrutinib for chronic lymphocytic leukemia.
Treatment: Nemtabrutinib · Ibrutinib · Acalabrutinib — The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anticancer therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USA Mitchell Cancer Institute ( Site 0014) · Mobile, Alabama
- Banner MD Anderson Cancer Center ( Site 0059) · Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) · Phoenix, Arizona
- Arizona Oncology Associates - NAHOA ( Site 8007) · Prescott, Arizona
- Alta Bates Summit Medical Center ( Site 0004) · Berkeley, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06136559 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages